InspireMD Inc
NASDAQ:NSPR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.85
3.39
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
InspireMD Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | IL |
Market Cap | 68.2m USD |
Operating Margin |
-439%
|
Country | JP |
Market Cap | 6.8T JPY |
Operating Margin |
28%
|
Country | CH |
Market Cap | 37.9B CHF |
Operating Margin |
13%
|
Country | DK |
Market Cap | 200.9B DKK |
Operating Margin |
27%
|
Country | US |
Market Cap | 16.9B USD |
Operating Margin |
17%
|
Country | KR |
Market Cap | 9.9T KRW |
Operating Margin |
-245%
|
Country | CA |
Market Cap | 6.9B USD |
Operating Margin |
4%
|
Country | CN |
Market Cap | 48.6B CNY |
Operating Margin |
46%
|
Country | US |
Market Cap | 6.3B USD |
Operating Margin |
32%
|
Country | US |
Market Cap | 6.1B USD |
Operating Margin |
12%
|
Country | UK |
Market Cap | 4.8B GBP |
Operating Margin |
13%
|
InspireMD Inc
Glance View
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on InspireMD Inc's most recent financial statements, the company has Operating Margin of -439%.